Navigation Links
New Study Provides Benchmarks for Optimizing Marketing Staff Levels to Drive Growth
Date:2/5/2009

CHAPEL HILL, N.C., Feb. 5 /PRNewswire/ -- In today's tough economy, maintaining operational efficiencies remains key, even while focusing on strategy and tactics to drive growth and profitability. In an effort to better understand the resources dedicated by biopharmaceutical companies to support marketing operations, a recent benchmark study was conducted by Best Practices, LLC, with insights available in the newly published report, "Benchmarks for Optimizing Marketing Staff Levels to Drive Growth." Data from this study were collected from more than sixty biopharma marketing leaders.

Benchmark data shares insights from a number of critical areas, including:

-- Staffing and productivity levels utilized across healthcare business models

    -- Growth and profit margin levels across biopharma portfolios
    -- Strategic and tactical activities that drive profitability & growth

The metrics shared in this study, segmented across pharma/biotech, medical devices and generic products, were gathered from across the biopharma industry including such companies as Abbott, Amgen, Baxter, Johnson & Johnson, Novartis, Pfizer, Roche, and Sanofi-Aventis.

    Key metrics found in the report include:
    -- Number of Products Supported Per Tactical Marketing FTE
    -- Number of Strategic Marketing FTEs per $100 Million
    -- Time & Activity Benchmarks for Strategic Marketing Staff
    -- Strategic Marketing Staff Benchmarks Across Key Activities
    -- Tactical Marketing Staff Benchmarks Across Key Activities

For more information on this report, contact Ben Gregory at bgregory@best-in-class.com or (919) 767-9160. To access the full report or download a complimentary copy of the report summary, go to www.best-in-class.com/rr977.htm.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more than 15 years, our highly credentialed research staff has conducted primary research exclusively for our Fortune 500 client base.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
2. Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant
3. New Study Provides Benchmarks for Winning Brand Team Management
4. New Study Shares Insights for Competitive Intelligence Policies, Ethics and Data Collection
5. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
6. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
7. Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing
8. Clinical Research Study Focuses on Little Known Behavioral Changes Related to Parkinsons Disease
9. Cardiovascular Side Effects of Pioglitazone and Rosiglitazone Linked to Vascular and Energy Pathways by Genomas Clinical Study
10. Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay
11. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 2017  SeraCare Life Sciences, Inc., a manufacturer ... diagnostics manufacturers and clinical laboratories, is announcing ... Inherited Cancer reference material for ... sequencing (NGS). The Seraseqâ„¢ Inherited Cancer DNA Mix ... industry experts to validate the ability of ...
(Date:3/23/2017)... YORK , March 23, 2017 ... ... of death, putting significant strain on health care systems, in ... cancer diagnoses rises, so too does the development of innovative ... minimum side effects. Among the many types of cancer treatments, ...
(Date:3/22/2017)... 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced ... U.K. Biobank and GSK to generate genetic sequence data from ... initiative will enable researchers to gain valuable insights to support ... range of serious and life threatening diseases. ... Genetic evidence has ...
(Date:3/22/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... ), a clinical-stage pharmaceutical company focused on ... today that Dr. Miriam Kidron , Oramed,s ... "Oral Insulin for Diabetes Treatment: Bypassing the Roadblock," ... Peptide Therapeutics (OPT) Boston Conference in Cambridge, ...
Breaking Biology Technology:
(Date:3/20/2017)... March 20, 2017 PMD Healthcare announces the ... and Wellness Management System (WMS), a remote, real-time lung ... 2010, PMD Healthcare is a Medical Device, Digital Health, ... dedicated to creating innovative solutions that empower people to ... intent focus, PMD developed the first ever personal spirometer, ...
(Date:3/13/2017)... Future of security: Biometric Face Matching software  Continue ... ... to match face pictures against each other or against large databases. The recognition ... ... software for biometric Face Matching on the market. The speed is at 100 ...
(Date:3/9/2017)... and MOUNTAIN VIEW, Calif. ... "Eating Well Made Simple," and 23andMe , the ... guide better food choices.  Zipongo can now provide customers ... food preferences, health goals and biometrics, but also genetic ... food choices. Zipongo,s personalized food decision support ...
Breaking Biology News(10 mins):